Eli Lilly and Company has reported encouraging long-term results for its biologic therapy Ebglyss (lebrikizumab-lbkz), demonstrating sustained skin clearance and significant itch relief for up to four years in patients with moderate-to-severe atopic dermatitis. The findings were presented at the American Academy of Dermatology Annual Meeting held in Denver from March 27–31.

The results are based on interim data from the ADlong phase IIIb open-label extension study, which evaluated once-monthly maintenance dosing of Ebglyss. According to the company, the majority of patients achieved near-complete skin clearance and meaningful reduction in persistent itch, with 80 percent maintaining outcomes without the use of topical corticosteroids. Additionally, 77 percent of patients were treated with Ebglyss as a monotherapy.

Ebglyss is an interleukin-13 (IL-13) inhibitor designed to target a key driver of inflammation in atopic dermatitis. By selectively blocking IL-13 signalling, the therapy addresses underlying disease mechanisms such as skin barrier dysfunction, chronic inflammation and itch.

The study also demonstrated a favourable safety profile, consistent with earlier trials. Most adverse events were mild to moderate, with no new safety concerns identified. Reported side effects included conjunctivitis and minor injection-site reactions, with no significant discontinuations linked to treatment.

Experts highlighted the significance of these findings in addressing unmet needs in eczema treatment. Emma Guttman-Yassky of the Icahn School of Medicine at Mount Sinai noted that patients with moderate-to-severe atopic dermatitis often face unpredictable disease flares and limited long-term control options. The four-year data suggest that Ebglyss could offer more consistent disease management and reduce flare frequency.

Further supporting evidence from a post-hoc analysis presented at the Maui Derm Hawaii 2026 indicated that patients on monthly maintenance dosing experienced fewer than one flare per year on average.

The ADlong study, which continues for an additional year, builds on Lilly’s broader clinical programme involving over 1,600 patients across multiple global trials. Ebglyss has already received regulatory approvals in the United States, Japan, Canada and the European Union for the treatment of moderate-to-severe atopic dermatitis in eligible patients aged 12 years and older.

With ongoing investments in immunology and dermatology, Lilly aims to expand treatment options that go beyond symptom management to deliver long-term disease control for patients living with chronic skin conditions.